Litigation Details for Gilead Sciences, Inc. v. Lupin Limited (D. Del. 2023)
Gilead Sciences, Inc. v. Lupin Limited (D. Del. 2023)
| Docket | 1:23-cv-00508 | Date Filed | 2023-05-09 |
| Court | District Court, D. Delaware | Date Terminated | 2025-02-18 |
| Cause | 35:271 Patent Infringement | Assigned To | Maryellen Noreika |
| Jury Demand | None | Referred To | |
| Patents | 10,039,718; 10,786,518 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Gilead Sciences, Inc. v. Lupin Limited
Details for Gilead Sciences, Inc. v. Lupin Limited (D. Del. 2023)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2023-05-09 | External link to document | |||
| 2023-05-09 | 3 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,039,718 B2 ;10,786,518 B2.… 9 May 2023 1:23-cv-00508 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Gilead Sciences v. Lupin Patent Litigation: Case No. 1:23-cv-00508
Gilead Sciences, Inc. v. Lupin Limited, No. 1:23-cv-00508, is a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Lupin’s proposed generic version of Biktarvy, Gilead’s fixed-dose HIV treatment containing bictegravir, emtricitabine, and tenofovir alafenamide. Gilead filed the action after receiving Lupin’s Paragraph IV certification challenging patents listed for Biktarvy. The case creates a potential 30-month FDA approval stay and places Gilead’s Biktarvy patent estate, rather than manufacturing capacity alone, at the center of generic-entry risk. [1]
What drug is at issue in Gilead v. Lupin?
The case concerns Biktarvy, a once-daily, single-tablet antiretroviral regimen.
| Product | Active ingredients | Sponsor | FDA indication |
|---|---|---|---|
| Biktarvy | Bictegravir sodium, emtricitabine, tenofovir alafenamide fumarate | Gilead Sciences | Treatment of HIV-1 infection in appropriate patients |
Biktarvy combines:
- Bictegravir, an integrase strand transfer inhibitor;
- Emtricitabine, a nucleoside reverse transcriptase inhibitor; and
- Tenofovir alafenamide, a nucleotide reverse transcriptase inhibitor.
The case is an ANDA dispute. Lupin is seeking approval for a therapeutically equivalent generic product rather than a biosimilar. The Biologics Price Competition and Innovation Act does not apply.
What patents protect Biktarvy in this litigation?
Gilead’s Biktarvy protection is layered across active-ingredient, combination, formulation, composition, and method-of-use claims. The asserted patents and listed patents can differ because the complaint reflects the patents selected by Gilead for enforcement against Lupin, while the FDA Orange Book reflects the patents submitted for listing against the approved product. [1][2]
Publicly identified Biktarvy patent families include the following core U.S. patents:
| Patent family or patent | General subject matter | Commercial significance |
|---|---|---|
| U.S. Patent No. 9,795,604 | Bictegravir-related compounds and pharmaceutical combinations | Core compound and combination protection |
| U.S. Patent No. 10,335,462 | Bictegravir-containing pharmaceutical compositions | Combination-product protection |
| U.S. Patent No. 10,849,919 | Bictegravir formulations and combinations | Formulation and product protection |
| U.S. Patent No. 11,020,404 | Bictegravir pharmaceutical compositions | Later-expiring composition protection |
| U.S. Patent No. 11,084,865 | Antiretroviral combinations and compositions | Extended portfolio coverage |
| U.S. Patent No. 11,174,868 | Bictegravir-containing compositions | Additional product protection |
| U.S. Patent No. 11,278,488 | Bictegravir combination technology | Layered generic-entry barrier |
| U.S. Patent No. 11,291,666 | Pharmaceutical compositions containing bictegravir | Later-filed formulation protection |
The exact claims asserted against Lupin must be determined from the complaint, infringement contentions, and any later claim-construction or summary-judgment filings. Patent families can also contain continuations with different expiration dates and claim scope.
What formulations are protected by Gilead’s Biktarvy patents?
The portfolio is directed primarily to the fixed-dose oral tablet and its active-ingredient combination. The relevant protection may cover:
- The bictegravir molecule and related salts;
- Combinations of bictegravir with emtricitabine and tenofovir alafenamide;
- Pharmaceutical compositions containing specified ratios or amounts of the active ingredients;
- Tablet formulations and excipient systems; and
- Treatment of HIV-1 using the fixed-dose combination.
Formulation claims are commercially important because they can remain relevant even if a generic manufacturer avoids a broader compound claim. A generic applicant may challenge each patent separately through Paragraph IV certifications and may argue that its proposed formulation does not infringe specific composition or excipient limitations.
When does Biktarvy lose exclusivity?
Biktarvy does not have a single exclusivity date. FDA regulatory exclusivity and patent exclusivity operate on separate timelines.
| Protection type | Relevant issue |
|---|---|
| New chemical entity exclusivity | Applies to the qualifying active ingredient, subject to FDA’s regulatory determination |
| New combination exclusivity | May protect the approved combination for a defined period |
| Orange Book patents | May delay approval if Gilead obtains the statutory litigation stay |
| Patent-term extension | May apply to an eligible patent but is limited by statutory rules |
| Pediatric exclusivity | May add six months to certain qualifying protections |
The principal commercial barrier is the remaining patent estate. Biktarvy’s earlier core patent protection extends into the 2030s, while later-issued composition and formulation patents may create additional barriers into the mid-2030s. The practical generic-entry date depends on:
- Which patents Lupin certified against;
- Which patents Gilead asserted;
- Whether the court finds the asserted claims valid and infringed;
- Whether any patent is delisted or expires;
- Whether Gilead and Lupin settle; and
- Whether Lupin obtains a judgment of noninfringement or invalidity.
A final patent expiration date should not be inferred from the latest patent number alone. Patent-term adjustment, patent-term extension, terminal disclaimers, continuations, and pediatric exclusivity can materially change the operative date.
What Paragraph IV challenges did Lupin make?
Lupin’s ANDA included Paragraph IV certifications asserting that the relevant Biktarvy patents were invalid, unenforceable, or not infringed. Gilead’s complaint followed the statutory notice process under the Hatch-Waxman Act. [1][3]
A Paragraph IV certification is a legal challenge, not evidence that the generic product has been approved. The certification permits the brand company to file an infringement action before FDA approval. If the brand company files within 45 days of receiving notice, FDA approval is generally stayed for up to 30 months, subject to earlier court resolution or other statutory events. [3]
The main legal issues in this type of case are expected to include:
- Claim construction;
- Infringement by Lupin’s proposed ANDA product;
- Obviousness of the claimed combination or formulation;
- Written description and enablement;
- Anticipation;
- Patent-term calculations;
- Scope of any terminal disclaimer; and
- Whether asserted patents are properly listed in the Orange Book.
What is the Orange Book status of Biktarvy?
Biktarvy is an FDA-approved small-molecule drug, so its relevant patents are listed in the FDA Orange Book rather than in the Purple Book used for biologic reference products. Orange Book listings identify patents and use codes that can trigger Paragraph IV litigation. [2]
The Orange Book does not determine whether a listed patent is valid or infringed. Listing gives the patent procedural significance in the ANDA process. The district court, not FDA, decides patent validity and infringement.
Because Biktarvy is a small-molecule tablet, biosimilar risk is not the correct analytical framework. The principal threat is generic substitution following ANDA approval under section 505(j) of the Federal Food, Drug, and Cosmetic Act.
What is the litigation status of Gilead v. Lupin?
The action was filed in the District of Delaware as Case No. 1:23-cv-00508. It is a patent-infringement action arising from Lupin’s ANDA filing for a generic Biktarvy product. [1]
The case should be evaluated through the following procedural milestones:
| Milestone | Significance |
|---|---|
| Complaint filed | Initiated the Hatch-Waxman action |
| Lupin answer and counterclaims | Defines invalidity, unenforceability, and noninfringement defenses |
| Rule 16 scheduling order | Establishes discovery and trial deadlines |
| Claim construction | Determines the meaning of disputed patent terms |
| Fact and expert discovery | Tests technical, regulatory, and commercial evidence |
| Summary judgment | May resolve infringement or validity before trial |
| Bench trial | Typical merits forum for pharmaceutical patent disputes in Delaware |
| Judgment or settlement | Determines whether and when generic approval can proceed |
No final commercial launch consequence follows from the filing alone. FDA approval remains subject to the ANDA review process, statutory stay provisions, patent judgments, and any settlement terms.
Which companies are challenging Gilead’s Biktarvy patents?
Gilead’s Biktarvy patent estate is exposed to multiple ANDA filers over time. Lupin is one challenger identified in the Delaware litigation. Other generic manufacturers may file separate ANDAs and trigger separate cases, often producing parallel litigation over overlapping patent families.
The competitive structure is different from a conventional product market. A generic applicant can obtain approval only after clearing FDA requirements and the applicable patent barriers. A court victory by one generic company does not necessarily authorize every other manufacturer to launch, although later cases may be influenced by the same claim-construction or validity rulings.
What generic entry risks exist for Biktarvy?
The principal risk is not immediate generic substitution. It is erosion of the expected duration and value of Biktarvy’s franchise if Lupin or another ANDA applicant defeats a core patent.
| Risk | Impact on Gilead |
|---|---|
| Invalidity ruling against a core patent | Can remove a major barrier for multiple ANDA applicants |
| Noninfringement ruling | May allow the challenged Lupin product to proceed after FDA approval |
| Narrow claim construction | Reduces coverage over alternative generic formulations |
| Settlement with an authorized launch date | Converts litigation risk into a defined erosion date |
| Patent delisting or expiration | Removes the associated Paragraph IV barrier |
| Manufacturing or supply dispute | Can delay launch even after patent clearance |
| At-risk launch | Creates potential damages, injunction, and market disruption |
Biktarvy has been one of Gilead’s major HIV products. A generic launch would affect product revenue, pricing, market share, and the value of the broader HIV portfolio. The impact would depend on the timing of entry, the number of approved competitors, payer substitution rules, and whether Gilead has an authorized-generic or other launch strategy.
How strong is Gilead’s Biktarvy patent estate?
The estate is structurally strong because it uses multiple layers of protection rather than relying on one patent. Core compound claims generally provide the broadest exclusionary coverage. Combination and formulation patents can extend practical protection but are more vulnerable to claim-specific invalidity and noninfringement arguments.
The strongest litigation position would normally arise where:
- The generic product necessarily contains the claimed active ingredients;
- The claim covers the commercial fixed-dose combination;
- The patent has a late expiration date;
- The specification provides substantial support for the claimed combination; and
- The asserted claim avoids narrow excipient or process limitations.
The most vulnerable patents are often later formulation patents with narrow structural or compositional limitations. Their value depends on whether the ANDA product necessarily meets each limitation.
Have Gilead and Lupin announced a settlement?
The public case record cited here does not establish a settlement, license, covenant not to sue, or agreed generic-entry date. A settlement would normally be reflected through a dismissal, consent judgment, stipulated judgment, or related filing. Any agreement would also be subject to federal antitrust reporting requirements under the Medicare Prescription Drug, Improvement, and Modernization Act. [4]
If the parties settle, the material terms would include:
- Lupin’s permitted launch date;
- Whether Lupin receives a license;
- Whether launch is authorized, contingent, or at risk;
- Any supply or royalty arrangement;
- Whether the agreement covers future continuation patents; and
- Whether the settlement affects other Gilead HIV products.
What does the case mean for Gilead’s revenue exposure?
Biktarvy’s value is concentrated in a high-volume chronic-treatment market. Generic entry would likely affect net price before it eliminates all branded demand. The magnitude of exposure depends on the date of entry and the number of competitors.
A first-filer or first commercial entrant can capture disproportionate volume, while multiple entrants generally accelerate price erosion. A settlement that delays Lupin’s launch but permits entry before the latest patent expiration could preserve substantial branded revenue while eliminating binary trial risk.
Key Takeaways
- Gilead Sciences v. Lupin, No. 1:23-cv-00508, is a Delaware Hatch-Waxman case concerning Lupin’s proposed generic Biktarvy product.
- Biktarvy contains bictegravir, emtricitabine, and tenofovir alafenamide.
- The dispute involves Paragraph IV patent challenges, not biosimilar substitution.
- Gilead’s protection is layered across compound, combination, composition, formulation, and method-of-use claims.
- The Orange Book creates the procedural framework, but the court determines validity and infringement.
- The principal commercial risk is a judgment or settlement permitting Lupin to enter before the latest practical patent barrier.
- No settlement or final generic launch date is established by the cited public record.
FAQs About Gilead v. Lupin and Biktarvy Patent Litigation
Is Biktarvy a biologic subject to biosimilar competition?
No. Biktarvy is an orally administered small-molecule tablet. Generic competition proceeds through the ANDA pathway, not the biosimilar pathway.
Can Lupin launch a generic Biktarvy product while the case is pending?
Only if FDA approval is available and the statutory patent stay has ended or been removed. Launching before final resolution can create substantial infringement and damages exposure.
Does a Paragraph IV certification mean that FDA approved Lupin’s product?
No. It means Lupin certified that the relevant patent is invalid, unenforceable, or not infringed. FDA approval remains a separate regulatory decision.
Do Biktarvy patents protect the tablet formulation or only bictegravir?
The portfolio includes both active-ingredient and combination or composition protection. The scope depends on the claims asserted in the specific litigation.
Could one court decision affect other Biktarvy generic challengers?
Yes. Claim construction or validity rulings may influence parallel cases, although each ANDA applicant’s product, defenses, and asserted patents must be evaluated separately.
References
-
Gilead Sciences, Inc. v. Lupin Limited, No. 1:23-cv-00508, Complaint, U.S. District Court for the District of Delaware (2023).
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
21 U.S.C. § 355(j).
-
Federal Trade Commission. (2024). Agreements filed under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. FTC.
More… ↓
